体外膜氧合治疗重度急性呼吸窘迫综合征
这项国际随机对照试验纳入极重度ARDS患者,比较立即静脉-静脉ECMO与常规治疗(含ECMO补救)的60天死亡率。结果显示ECMO组死亡35%,对照组46%,差异未达统计学显著(RR 0.76,95%CI 0.55-1.04,P=0.09),但ECMO组输血性出血和严重血小板减少更多,缺血性卒中更少。
要点
- 极重度ARDS中,立即ECMO较常规治疗未显著降低60天死亡率。
- ECMO组输血性出血(46% vs 28%)和严重血小板减少(27% vs 16%)更多。
- 对照组28%交叉至ECMO,其中57%死亡,可能稀释意向性分析效应。
核心结论
- 在极重度ARDS患者中,立即静脉-静脉ECMO相比包含ECMO补救的常规机械通气策略,未显著降低60天死亡率。
研究设计与样本
- 国际随机对照试验,纳入极重度ARDS患者,ECMO组124例,对照组125例。
- 极重度ARDS定义满足以下任一:Pao2:Fio2<50 mmHg超过3小时;Pao2:Fio2<80 mmHg超过6小时;或动脉血pH<7.25伴PaCO2≥60 mmHg超过6小时。
- 对照组难治性低氧血症患者允许交叉至ECMO。
- 主要终点为60天死亡率。
主要发现
- 60天时ECMO组死亡44/124例(35%),对照组57/125例(46%),相对风险0.76(95%CI 0.55-1.04,P=0.09)。
- 对照组35例(28%)随机后平均6.5±9.7天交叉至ECMO,其中20例(57%)死亡。
- ECMO组输血性出血46% vs 对照组28%,绝对风险差18个百分点(95%CI 6-30)。
- ECMO组严重血小板减少27% vs 对照组16%,绝对风险差11个百分点(95%CI 0-21)。
- ECMO组缺血性卒中0例 vs 对照组5%,绝对风险差-5个百分点(95%CI -10至-2)。
关键数值与推荐
- 主要终点60天死亡率:ECMO组35% vs 对照组46%,RR 0.76(95%CI 0.55-1.04,P=0.09)。
- 输血性出血:ECMO组46% vs 对照组28%,绝对风险差18个百分点(95%CI 6-30)。
- 严重血小板减少:ECMO组27% vs 对照组16%,绝对风险差11个百分点(95%CI 0-21)。
- 缺血性卒中:ECMO组0% vs 对照组5%,绝对风险差-5个百分点(95%CI -10至-2)。
临床怎么用
- 对极重度ARDS,常规机械通气联合ECMO补救治疗可作为策略之一,立即ECMO未显示显著生存获益。
- 选择ECMO时应权衡出血和血小板减少风险增加,以及缺血性卒中风险降低。
局限性
- 对照组28%交叉至ECMO,可能削弱意向性分析中ECMO的效应估计。
- 研究未报告其他可能影响结果解释的局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe acute respiratory distress syndrome (ARDS) remains controversial. METHODS: In an international clinical trial, we randomly assigned patients with very severe ARDS, as indicated by one of three criteria - a ratio of partial pressure of arterial oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 50 mm Hg for more than 3 hours; a Pao2:Fio2 of less than 80 mm Hg for more than 6 hours; or an arterial blood pH of less than 7.25 with a partial pressure of arterial carbon dioxide of at least 60 mm Hg for more than 6 hours - to receive immediate venovenous ECMO (ECMO group) or continued conventional treatment (control group). Crossover to ECMO was possible for patients in the control group who had refractory hypoxemia. The primary end point was mortality at 60 days. RESULTS: At 60 days, 44 of 124 patients (35%) in the ECMO group and 57 of 125 (46%) in the control group had died (relative risk, 0.76; 95% confidence interval [CI], 0.55 to 1.04; P=0.09). Crossover to ECMO occurred a mean (±SD) of 6.5±9.7 days after randomization in 35 patients (28%) in the control group, with 20 of these patients (57%) dying. The frequency of complications did not differ significantly between groups, except that there were more bleeding events leading to transfusion in the ECMO group than in the control group (in 46% vs. 28% of patients; absolute risk difference, 18 percentage points; 95% CI, 6 to 30) as well as more cases of severe thrombocytopenia (in 27% vs. 16%; absolute risk difference, 11 percentage points; 95% CI, 0 to 21) and fewer cases of ischemic stroke (in no patients vs. 5%; absolute risk difference, -5 percentage points; 95% CI, -10 to -2). CONCLUSIONS: Among patients with very severe ARDS, 60-day mortality was not significantly lower with ECMO than with a strategy of conventional mechanical ventilation that included ECMO as rescue therapy. (Funded by the Direction de la Recherche Clinique et du Développement and the French Ministry of Health; EOLIA ClinicalTrials.gov number, NCT01470703 .).
引用
- Combes A, Hajage D, Capellier G, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018. PMID: 29791822. doi:10.1056/NEJMoa1800385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。